In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Kazia Therapeutics, with a price target of $20.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Naz Rahman has given his Buy rating due to a combination of factors that highlight Kazia Therapeutics’ promising developments in oncology. The company’s lead asset, paxalisib, is being developed for both glioblastoma multiforme (GBM) and triple-negative breast cancer (TNBC), with encouraging data emerging from ongoing trials. The potential for paxalisib to provide a significant clinical benefit in GBM, despite missing a primary endpoint, is underscored by its demonstrated overall survival advantage compared to the standard of care.
Furthermore, the initial positive data from the Phase 1b trial of paxalisib in TNBC, particularly in combination with other therapies like Keytruda and Lynparza, suggests the drug’s potential to resensitize tumors and reduce tumor burden. This, combined with the strategic partnership with QIMR Berghofer Medical Research Institute, positions Kazia well for future advancements. The upcoming data presentation at the San Antonio Breast Cancer Symposium could further catalyze the stock, reinforcing the Buy recommendation.
Rahman covers the Healthcare sector, focusing on stocks such as Kazia Therapeutics, Silexion Therapeutics, and Vivani Medical. According to TipRanks, Rahman has an average return of -11.5% and a 32.15% success rate on recommended stocks.